Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

About this update from Enanta Pharmaceuticals, Inc.

WATERTOWN, Mass., April 07, 2026 --( BUSINESS WIRE )-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data on zelicapavir, an oral, once-daily, N-protein inhibitor, in development for the treatment of (RSV) have been accepted for two oral presentations at the European Society of Clinical Microbiology & Infectious Diseases Global 2026 (ESCMID) being held April 17-21, 2025 in Munich, Germany. The first oral presentation will include results from RSVHR, the Phase 2b study of zelicapavir in high-risk adults, which were announced in September 2025, showing about a week improvement in complete symptom resolution and a lower hospitalization rate, and featuring new findings demonstrating strong exposure multiples over the EC 90 . The second oral presentation will highlight new data confirming zelicapavir’s high clinical and functional barrier against antiviral resistance, generated from the Phase 2 study in pediatric patients, which was announced in September 2024. Details of the presentations are as follows: Presentation Title: Zelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSV Abstract Number: 3963 Date: April 18, 2026 Time: 8:30 a.m. CEST / 2:30 a.m. EDT Location: Hall A1-3 Session Type: 2-hour Oral Session Session Title: Three viruses, one winter: what we miss, what we treat, what comes next Presenter: Scott T. Rottinghaus, M.D. ePoster Title: Zelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trial Abstract Number: 5360 Date: April 18, 2026 Time: 8:30 a.m. CEST / 2:30 a.m. EDT Location: Arena 2 ePoster Number: E0043 Session Type: ePoster Flash Session Session Title: Old viruses, new weapons: emerging antiviral therapies from bench to bedside Presenter: John P. DeVincenzo, M.D. Further information about ESCMID Global 2026 can be found here . Presentations will be available on the Company’s website here following each presentation. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20260407155688/en/ Contacts Media and Investors: Jennifer Viera 617-744-3848 [email protected]

View stock analysis, news, and events for Enanta Pharmaceuticals, Inc.